25 May 2013
Keywords: Merck Serono, Merck KGaA, NSCLC vaccine, L-BLP25, Stimuvax, Ph III, Oncothyreon
Article | 20 December 2012
Merck Serono, a division of Germany’s Merck KGaA (MRK: DE), Darmstadt, says that the Phase III START trial ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 December 2012
24 May 2013
© 2013 thepharmaletter.com